Device Family Grouping under a Single Registro Sanitario

1. Key takeaways

Mexico permits several models and variants of the same device family to be combined into a single registro sanitario, so that official fees are charged for one registration and one shared dossier serves the whole group. The boundaries of the group are set jointly by the intended use, the design principle and the risk classification; models that fall outside these boundaries cannot be merged in, and if they are, they will be required to be split out again at a later amendment or inspection. Grouping is therefore both a cost lever and a compliance discipline: the economics reward broad families, while the regulatory rules reward accurately bounded ones. The design task is to find the widest family that the three boundary lines genuinely support, and to document that reasoning so it can be defended later. This page explains where the financial value of grouping comes from, the three lines that delimit a family, how new models are added after registration, why the new labeling standard makes model identification mandatory, and why grouping under the abbreviated pathway is even stricter than under the standard route.

2. Legal basis

The grouping framework draws on the risk classification and dossier rules of the implementing regulation, the fee structure of the federal rights law, and the mandatory labeling elements of the new standard. The table below lists each instrument with its articles or date and the point it establishes.

3. Expert insights

Insight 1: the economic value of grouping lies in fees and cycle time. Official fees are charged per registration item, so one registration covering many models costs less than several single-model registrations, and the review also runs once instead of once per model. For consumable product lines with large model counts, this is the most direct cost-reduction instrument available, and it should be quantified before the dossier architecture is fixed rather than discovered afterwards. The saving compounds further when later models are added, since a family amendment is lighter than a fresh registration.

Insight 2: the grouping boundary has three lines. The intended use must be the same or highly similar, the design and working principle must be the same, and the risk classification must be the same. Models across different risk classifications cannot be combined into one registration, because both the depth of documentation and the fee tier differ between classifications. A product line that spans classifications is necessarily a product line of several registrations, however inconvenient that may be commercially. Forcing cross-classification models into one family saves fees at registration time and repays the saving with interest at the first amendment or inspection.

Insight 3: adding models after registration requires an amendment. Adding a model within the family is not an internal registry matter; it must go through the amendment (Modificación) procedure, with fees charged as a proportion of the registration fee. Treating the grouping as unlimited expansion capacity, where new models are quietly absorbed into the family, plants a compliance problem that surfaces precisely when the certificate is needed most, such as during an inspection or a transfer. Every new model should enter through the amendment door, with its fee and its timeline, not through the warehouse door.

Insight 4: NOM-137-SSA1-2025 turns model identification into a mandatory element. The new labeling standard requires the catalogue number, model and version number to be marked; content that was previously optional is now mandatory. The labeling system of a grouped registration must be rearranged under the new standard, and every model in the family must remain individually identifiable on its labeling, so that the group never obscures the identity of the specific unit sold. For a family with many catalogue numbers, this usually means reworking the label templates and the master data together.

Insight 5: under the abbreviated pathway, grouping is stricter still. The abbreviated pathway requires full identity between the product and the reference approved version, and every model within the group must be traceable to a corresponding approval in the reference certificate. Where the reference approval covers only part of the models, the remaining models proceed under the standard pathway; the group cannot inherit eligibility that its members do not individually possess. The matching exercise should therefore be done model by model, before the group is submitted as a single abbreviated application.

4. Practical recommendations

• Finalize the grouping plan before dossier preparation, and write it up as a family definition document stating the inclusion and exclusion criteria.
• Following Articles 179 and 180 of the RIS, present in the dossier a comparison of the structure, materials and functions of each model within the family.
• Split product lines that span risk classifications into several registrations instead of forcing a merger to save fees.
• Budget and schedule the amendment procedure for new models in advance, calculating the cost as a proportion of the registration fee.
• Complete the labeling with catalogue number, model and version number under NOM-137-SSA1-2025, and work backwards from the effective date (360 calendar days after publication).

5. Verification checklist

• □ The family definition document has been finalized, with inclusion and exclusion criteria
• □ Models in the group share the same intended use, design principle and risk classification
• □ The dossier contains the structure, materials and function comparison for each model
• □ The amendment budget and schedule for new models has been planned
• □ The labeling includes the catalogue number, model and version number
• □ Under the abbreviated pathway, every model can be matched to the reference approval

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com